Bristol Myers Squibb has acquired Nvidia's Vera Rubin DGX SuperPOD, making it the first pharmaceutical company to put the chipmaker's latest AI computing system to work. The drugmaker plans to use the system to speed up drug discovery, cutting years off the typical research timeline.
What is the Vera Rubin DGX SuperPOD?
Nvidia's DGX SuperPODs are purpose-built clusters of graphics processing units designed for AI training and inference. The Vera Rubin iteration is the company's newest generation, packing more computing power into a single system. While Nvidia has not disclosed full specs for the Vera Rubin model, the SuperPOD family is known for handling massive datasets and complex machine learning models.
For Bristol Myers, the system will run AI models that analyze biological data, predict how molecules behave, and suggest candidate compounds for diseases. The company's researchers will train models on proprietary and public data sets, looking for patterns that might lead to new drugs.
Why Drug Discovery Needs AI
Bringing a new medicine to market typically takes more than a decade and costs billions. Much of that time is spent in early-stage research, where scientists test thousands of compounds against a target. AI can screen virtual libraries of molecules in days, flagging the most promising ones for lab testing.
Bristol Myers already uses AI in parts of its pipeline, but the Vera Rubin SuperPOD represents a leap in scale. The system can handle models that were too large or slow to train on older hardware. That means researchers can explore more complex biological questions — like how a protein folds or how a drug interacts with multiple targets at once.
First Mover in Pharma
No other pharmaceutical company has deployed the Vera Rubin DGX SuperPOD. Bristol Myers is the first, giving it early access to Nvidia's latest hardware. The move signals that the company is betting big on AI to maintain a competitive edge in drug development.
Other drugmakers have invested in AI, but often through partnerships with cloud providers or by buying smaller systems. Bristol Myers chose to own the hardware in-house, which gives it full control over the data and the workload. That could matter for sensitive patient data and proprietary research.
The Vera Rubin SuperPOD is being installed at a Bristol Myers facility. The company hasn't said which specific projects will be the first to use the system, but it's likely to run across multiple therapeutic areas. Oncology and immunology are key focuses for the drugmaker.
Nvidia has been pushing its DGX systems into industries beyond tech, including healthcare, finance, and manufacturing. The Bristol Myers deal is a win for that strategy, giving the chipmaker a high-profile pharma customer to point to when selling to other life sciences companies.
